Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). Patients and Methods: Patients received 1 cycle of subcutaneous (SC) azacitidine (75 mg/m 2) on the first 7 days of cycle 1, followed by oral azacitidine daily (120 to 600 mg) on the first 7 days of each additional 28-day cycle. Pharmacokinetic and pharmacodynamic profiles were evaluated during cycles 1 and 2. Adverse events and hematologic responses were recorded. Cross-over to SC azacitidine was permitted for nonresponders who received ≥ 6 cycles of oral azacitidine. Results: Overall, 41 patients received SC and oral azacitidine (MDSs, n = 29; CMML, n = 4; AML, n = 8). Dose-limiting toxicity (grade 3/4 diarrhea) occurred at the 600-mg dose and MTD was 480 mg. Most common grade 3/4 adverse events were diarrhea (12.2%), nausea (7.3%), vomiting (7.3%), febrile neutropenia (19.5%), and fatigue (9.8%). Azacitidine exposure increased with escalating oral doses. Mean relative oral bioavailability ranged from 6.3% to 20%. Oral and SC azacitidine decreased DNA methylation in blood, with maximum effect at day 15 of each cycle. Hematologic responses occurred in patients with MDSs and CMML. Overall response rate (ie, complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously untreated patients. Conclusion: Oral azacitidine was bioavailable and demonstrated biologic and clinical activity in patients with MDSs and CMML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · cited 1×
“Baseline characteristics for the remaining 41 patients who received oral azacitidine are presented in Table 1.(11) Cytogenetic data were available at baseline for 35 of 41 patients treated with oral azacitidine; nearly half of the patients had normal karyotype, approximately 25% had a single abnormality, and nearly 20…”
BackgroundVardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424 · cited 1×
“Patients Eligible patients were 18 years, had an Eastern Cooperative Oncology Group performance status score of 0 to 2, and a diagnosis of MDSs, CMML, or AML according to WHO classification.(6,7) For patients with AML, eligibility was limited to those for whom standard curative measures did not exist or were no longer…”
MethodMissing Value Estimation Methods for DNA Microarrays
Troyanskaya, O., Cantor, M., Sherlock, G., Brown, P., Hastie, T., Tibshirani, R., Botstein, D., & Altman, R. B. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.6.520 · Cited by 4,230 · cited 1×
“knnimpute function from the R package pamr.(8) Wilcoxon signed-rank tests were performed to identify loci with significant methylation differences at each post-treatment time point versus baseline; P .”
MethodCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197 · cited 1×
“Patients Eligible patients were 18 years, had an Eastern Cooperative Oncology Group performance status score of 0 to 2, and a diagnosis of MDSs, CMML, or AML according to WHO classification.(6,7) For patients with AML, eligibility was limited to those for whom standard curative measures did not exist or were no longer…”
MethodCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Gore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 474 · cited 2×
“This pattern has been observed in other azacitidine studies.(3,12) At the dosing schedule employed in this study, oral azacitidine affected fewer loci than SC azacitidine; however, 1,482 loci were identified as commonly hypomethylated by both azacitidine formulations.”
BackgroundSelf-citationSoriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078576 · Cited by 390 · cited 1×
“This pattern has been observed in other azacitidine studies.(3,12) At the dosing schedule employed in this study, oral azacitidine affected fewer loci than SC azacitidine; however, 1,482 loci were identified as commonly hypomethylated by both azacitidine formulations.”
Self-citationA Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Hollenbach, P. W., Nguyen, A. N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S. L., Heise, C., & MacBeth, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009001 · Cited by 362 · cited 2×
“© 2011 by American Society of Clinical Oncology INTRODUCTION Azacitidine is a cytidine nucleoside analog with a mechanism of action that involves incorporation into DNA and RNA.1,2 Data suggest that patients must be exposed to azacitidine over several treatment cycles for optimal therapeutic effect.3 The requirement f…”
BackgroundSelf-citation
Cited by
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Wei, A. H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J.-H., Porkka, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004444 · Cited by 445
Self-citationThe future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Montalban‐Bravo, G. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 187
“that lower exposures, as determined by pharmacokinetic profiling, resulted in significant clinical activity.(87,111) Based on this information, at MD Anderson, we designed a series of clinical trials investigating atten-”
MethodSelf-citationA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Diesch, J., Zwick, A., Garz, A.-K., Palau, A., Buschbeck, M., & Götze, K. S. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0237-y · Cited by 173
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“Maximal effects were observed at day 15, but methylation levels returned to near-baseline level by the end of each cycle (day 28) (Garcia-Manero et al., 2011).”
BackgroundSaunthararajah, Y. (2013) · Hematology · doi:10.1182/asheducation-2013.1.511 · Cited by 79
Current and emerging strategies for management of myelodysplastic syndromes
Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70
Metadata
- Authors
- Garcia-Manero, G., Gore, S. D., Cogle, C., Ward, R., Shi, T., MacBeth, K. J., Laille, E., Giordano, H., Sakoian, S., Jabbour, E., Kantarjian, H., & Skikne, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-20
- Volume
- 29
- Issue
- 18
- Pages
- 2521-2527
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148428508
- Cited by
- 252
- References
- 15
- FWCI
- 13.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.